Moroxite Receives Second FDA Breakthrough Device Designation
Moroxite AB, a Swedish medical technology company developing biomaterials for bone healing in spinal surgery, has received its second Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The designation was granted to the company’s product candidate Xerafuse™ TOB, a tobramycin-eluting, resorbable bone graft extender for spinal fusion surgery. The breakthrough designation gives Moroxite opportunities for closer interaction with the FDA and prioritized review of future regulatory submissions.
Lund, Sweden, November 17, 2026 – Xerafuse™ TOB is intended for use as a bone graft extender in spinal fusion surgery of the sacrolumbar spine in patients at increased risk of infection. The resorbable material is designed to support bone regeneration. It also releases the antibiotic tobramycin to help prevent bacterial colonization of the bone graft substitute following surgery, with the aim of providing an environment conducive to bone healing.

Moroxite’s lead product, Xerafuse™ BMP, received FDA Breakthrough Device Designation in 2025. It is being developed to stimulate bone formation and eliminate the need to harvest bone from patients in certain spinal fusion procedures.
“Receiving a second FDA Breakthrough Device Designation is an important milestone for Moroxite. Xerafuse BMP and Xerafuse TOB are based on the same biomaterial platform but are designed to address different clinical needs in spinal fusion surgery. Our goal is to develop solutions that can improve bone healing and help reduce complications for patients,” says Fredrik Lindberg, CEO of Moroxite.
The FDA’s Breakthrough Devices Program aims to facilitate the development and expedite the review of medical devices with the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions.



